Form 4: Tempest Therapeutics Director Acquires Stock Options

Tempest Therapeutics Director Michael Raab acquired 1,230 stock options with an exercise price of $2.94, vesting by early 2027.

Summary

• Michael Raab, a Director at Tempest Therapeutics, Inc. (TPST), acquired 1,230 stock options.
• The options have an exercise price of $2.94 per share.
• The acquisition occurred on January 27, 2026.
• The underlying shares will vest in full on the earlier of January 27, 2027, or the date of the Issuer's 2026 annual stockholder meeting, contingent on continuous service.
• The acquired stock options are exercisable until their expiration date of January 26, 2036.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating insider confidence. However, it's a routine compensation event rather than a major strategic announcement, hence a moderate score.

Positives

• A Director acquiring stock options can signal confidence in the company's future performance and strategic direction.
• The long expiration date of January 26, 2036, provides ample time for the stock price to potentially appreciate above the exercise price of $2.94.

Negatives

• The acquired options are not immediately exercisable, with vesting contingent on future service and specific dates, introducing a time-based condition for realization of value.

Risks

• The value of the stock options is directly dependent on the future market price of Tempest Therapeutics, Inc. common stock exceeding the $2.94 exercise price.
• Vesting of the options is subject to the Director's continuous service through the vesting date, meaning the options could be forfeited if service is terminated prematurely.

Future Outlook

The grant of stock options to a director suggests an expectation of future stock price appreciation, aligning management incentives with long-term shareholder value and reflecting confidence in the company's strategic trajectory.

Industry Context

In the biotechnology and pharmaceutical sectors, equity grants like stock options are a common form of executive and director compensation. This practice is designed to incentivize long-term performance and align the interests of leadership with shareholders, particularly given the often lengthy development cycles and significant regulatory hurdles inherent in the industry.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across many industries, including biotech, to align their interests with shareholders and encourage long-term commitment.
• The vesting schedule, tied to either a specific date or the annual meeting, is typical for director equity awards, ensuring continued engagement and service.
• An exercise price equal to the market price on the grant date (implied by a $0 option price and an acquisition) is common for incentive stock options, providing upside potential only if the stock price increases.

Stakeholder Impact

• Shareholders: Potentially positive, as the director's financial interests are further aligned with the company's stock performance, incentivizing value creation.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Monitor the vesting of the 1,230 stock options on or before January 27, 2027.
• Observe the company's 2026 annual stockholder meeting date, as it could trigger earlier vesting of the options.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. While it signals insider confidence, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard governance and compensation disclosure.

Keywords

Tempest Therapeutics, TPST, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals